Takeda Pharmaceuticals and Eli Lilly announced that they plan to challenge a $9 billion judgment in a lawsuit that alleged Actos caused a patient's bladder cancer.
Takeda Pharmaceuticals U.S.A., Inc. and Eli Lilly and Company announced that the companies plan to challenge the $9 billion judgment awarded by a jury in a lawsuit that alleged that Actos caused a patient’s bladder cancer.
In the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al., a jury in United States District Court, Western District Louisiana found in favor of the plaintiffs and awarded $1.475 million in compensatory damages. The allocation of liability was 75% Takeda and 25% Eli Lilly. The jury also awarded $6 billion in punitive damages from Takeda and $3 billion from co-defendant, Eli Lilly.
“Takeda respectfully disagrees with the verdict and we intend to vigorously challenge this outcome through all available legal means, including possible post-trial motions and an appeal,” said Kenneth D. Greisman, senior vice president, general counsel, Takeda Pharmaceuticals U.S.A., Inc. in a company statement. “We have empathy for the Allens, but we believe the evidence did not support a finding that Actos caused his bladder cancer. We also believe we demonstrated that Takeda acted responsibly with regard to Actos.”
"While we have empathy for the plaintiff, we believe the evidence did not support his claims," said Mike Harrington, senior vice president and general counsel. "Lilly disagrees with the verdict and we intend to vigorously challenge this outcome through all available legal means."
In June 2011, FDA issued a warning that there is an increase in bladder cancer risk in people who used the drug for longer than a year. The agency required that the cancer risk be added to the medication's warning label.
Judgments were entered in Takeda's favor in three previous Actos trials. Lilly was not named previously. This is the first federal case to be tried and the first in the consolidated Actos multidistrict litigation, the companies report. Lilly copromoted Actos with Takeda from 1999 to 2006.
Under Lilly's agreement with Takeda, Lilly will be indemnified by Takeda for its losses and expenses with respect to the US litigation and other related expenses in accordance with the terms of its indemnification agreement.
Sources:
Takeda Pharmaceuticals U.S.A., Inc. Eli Lilly and CompanyFDA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.